His words reflect a truth understood by researchers and clinicians across cancer care, that progress is rarely the result of a single breakthrough, but rather the collective work of researchers, clinicians and patients building knowledge over time.
This sentiment is shared by Icon’s Director of Medical Oncology Associate Professor Louise Nott.
“Cancer research is about building on the knowledge of research done by our predecessors. It’s the belief that every finding can become a foundation for the next treatment,” said A/Prof Nott.
Professor Scolyer’s final message was also a clear call to continue investing in research and clinical trials.
“To my research and clinical colleagues, I implore you to stay inquisitive and brave and keep striving to break new ground. And to government and the wider community, please keep funding science and medical research. This is the most impactful way that you too can make a difference,” he wrote.
As Icon Group’s Global Chief Medical Officer, Dr Ian Irving, notes, this collective effort is what drives progress in cancer care.
“Every study, every participant and every insight contributes to the growing body of knowledge that helps shape the future of cancer care. At Icon, this principle underpins our commitment to supporting clinical trials and advancing cancer research,” said Dr Irving.
This commitment continues through Icon Cancer Foundation’s support of clinical trials and research programs aimed at improving cancer care for current and future generations.